NEW YORK (GenomeWeb News) – Susan G. Komen for the Cure, a non-profit breast cancer research advocacy organization, has teamed with American Airlines to raise $8 million to support a project at the University of Texas’ MD Anderson Cancer Center that will use genomics, proteomics, and nanotechnology to study and treat inflammatory breast cancer.
Under the terms of the agreement, American will raise $7.5 million for Komen's first Promise Grant, which will support the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic for eight years.
The focus of the research will be to discover ways to diagnose IBC earlier and to develop treatments tailored to the disease.
IBC is a rare but aggressive form of breast cancer that is not detectable by mammography or ultrasound, and which is “often resistant to existing breast cancer treatments,” Komen for the Cure said.
Komen said it started the Promise Grants program to get researchers to collaborate in new ways to develop breast cancer diagnostic tools and treatments.